BridgeMD
New treatment option for Mpox
Official title Mpox Comprehensive Assessment for Responsive Immunisation in Emergency Outbreaks
ClinicalTrials.gov ID: NCT06887556
What this study is testing
- What it's testing
- The MPXV CARE study principally aims to use clinical and epidemiology data to target specific individuals willing and able to provide appropriate and proportionate biological samples to develop novel immune diagnostics that support models of disease burden and future vaccine utilisation.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 5 to 80. Healthy volunteers may be eligible.
You may be able to join if
- Healthy males and females aged between ages 5-80 years, who are able and willing to provide informed consent and will comply with the study...
- Group 1 (suspected exposure cohort) only
- Live within or adjacent to an epidemiologically identified region of Mpox transmission
- Close contacts of those with microbiologically confirmed Mpox
- Group 2 (post-exposure/vaccinated cohort) only
You likely can't join if
- Unwilling or unable to provide informed consent to take part
- Unwilling or unable to comply with study procedures
- History of any suspected or confirmed disorder of the immune system that, in the opinion of the investigators, might impair the results of the study
- Have a bleeding disorder deemed significant by a member of the study team
- Pregnant or breast-feeding females
- Group 1 (suspected exposure cohort) only
See the full eligibility criteria
- Healthy males and females aged between ages 5-80 years, who are able and willing to provide informed consent and will comply with the study requirements.
- Group 1 (suspected exposure cohort) only
- Live within or adjacent to an epidemiologically identified region of Mpox transmission
- Close contacts of those with microbiologically confirmed Mpox
- Group 2 (post-exposure/vaccinated cohort) only
- Previous clinically or microbiologically confirmed Mpox or confirmed previous vaccination with a smallpox/MVA vaccine
- Fully recovered from Mpox infection
- Group 3 (control cohort) only:
- Asymptomatic with no known exposure to Mpox
- Unwilling or unable to provide informed consent to take part
- Unwilling or unable to comply with study procedures
- History of any suspected or confirmed disorder of the immune system that, in the opinion of the investigators, might impair the results of the study
- Have a bleeding disorder deemed significant by a member of the study team
- Pregnant or breast-feeding females
- Group 1 (suspected exposure cohort) only
- Known history of Mpox infection
- Current symptoms consistent with Mpox
- Known exposure to Mpox in the last month
- Group 2 (post-exposure/vaccinated cohort) only
- Participants with any ongoing symptoms of Mpox, indicating incomplete recovery.
- Group 3 (control cohort only)
- Symptoms of Mpox
- Known exposure to Mpox in the last month
The study team makes the final eligibility decision.
Where it's taking place
- Kigali, Rwanda
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 5 years to 80 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kigali, Rwanda. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.